Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00353145 · ClinicalTrials.gov registry record · Phase 2
Gemox as First and Second Line Therapy in Unknown Primary Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00353145: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00353145 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00353145, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
Primary objectives: 1. To determine the overall tumor response rate with oxaliplatin in combination with gemcitabine (GEMOX) as first line and second line therapy in unknown primary cancer (UPC). 2. To determine the tolerability (toxicity) of this regimen in this patient population. Secondary objectives: 1. To determine the median overall survival (OS) and time to progression (TTP) for patients treated with this combination. 2. To determine the impact of this combination on quality of life (QOL) in this patient population.
Interventions
- DRUG Oxaliplatin
- BEHAVIORAL Questionnaire
- DRUG Gemcitabine (Gemox)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2004-02 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00353145
The ClinicalTrials.gov registry entry for NCT00353145 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Oxaliplatin is the first listed.
NCT00353145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00353145 about?
NCT00353145 is a clinical study titled "Gemox as First and Second Line Therapy in Unknown Primary Cancer". Primary objectives: 1. To determine the overall tumor response rate with oxaliplatin in combination with gemcitabine (GEMOX) as first line and second line therapy in unknown primary cancer (UPC). 2. To determine the tolerability (toxicity) of this regimen in this patient population. Secondary obje...
What is the current status of trial NCT00353145?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2004-02. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00353145?
The interventions under investigation include: Oxaliplatin (DRUG), Questionnaire (BEHAVIORAL), Gemcitabine (Gemox) (DRUG).
Who is sponsoring clinical trial NCT00353145?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.